Answers are grounded in this paper and cite their sources.
Introduction: In spite of the high prevalence of dyslipidemia in systemic lupus erythematosus (SLE) and its role in patients’ cardiovascular and kidney diseases, few studies had been conducted in this regard. Objectives: We aimed to study the relation between dyslipidemia and disease activity in SLE patients in Iran. Patients and Methods: This analytical cross-sectional study was conducted on SLE patients. The activity of disease was determined by SLE disease activity index (SLEDAI). The serum level of triglyceride (TG), cholesterol, low-density lipoprotein (LDL-C), and high-density lipoprotein (HDL-C) were measured. The correlation between dyslipidemia and SLE disease activity was assessed. Results: Around 62 out of 71 patients (87%) were female (mean age was 34 years). The mean disease duration was 1 year. Around 49% of patients had active disease (SLEDAI ≥6). Proteinuria and nephritis were observed in 18% and 24%, respectively. About 62% of patients had at least one abnormality in their lipid profile. High cholesterol (>200 mg/dL), high TG (>150 md/dL), high LDL-C (>130 mg/dL) and low HDL-C (<50 mg/dL in females and <40 md/dL in males) levels were observed in 25%, 42%, 20% and 49% of patients, respectively. Patients with active disease had lower age and shorter disease duration in comparison to the others (P<0.05). There were no differences in gender and weight between patients in active and inactive phases (P>0.05). Patients with active disease had higher serum cholesterol, TG and LDL-C levels and lower levels of serum HDL-C. Conclusion: It seems that there is a relationship between disease activity and lipid profile abnormalities in SLE patients.
No takes yet. Share an insight, caveat, or question.
Hajian et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: